BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 30672842)

  • 21. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.
    Stabile A; Pellegrino A; Mazzone E; Cannoletta D; de Angelis M; Barletta F; Scuderi S; Cucchiara V; Gandaglia G; Raggi D; Necchi A; Karakiewicz P; Montorsi F; Briganti A
    Eur Urol Oncol; 2022 Feb; 5(1):1-17. PubMed ID: 34538770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer.
    Meijer D; de Barros HA; van Leeuwen PJ; Bodar YJL; van der Poel HG; Donswijk ML; Hendrikse NH; van Moorselaar RJA; Nieuwenhuijzen JA; Oprea-Lager DE; Vis AN
    J Urol; 2021 Jun; 205(6):1655-1662. PubMed ID: 33530746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series.
    Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
    Eur Urol; 2020 Dec; 78(6):779-782. PubMed ID: 32624281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of
    Fossati N; Scarcella S; Gandaglia G; Suardi N; Robesti D; Boeri L; Karnes RJ; Heidenreich A; Pfister D; Kretschmer A; Buchner A; Stief C; Battaglia A; Joniau S; Van Poppel H; Osmonov D; Juenemann KP; Shariat S; Hiester A; Nini A; Albers P; Tilki D; Graefen M; Gill IS; Mottrie A; Galosi AB; Montorsi F; Briganti A
    J Urol; 2020 Aug; 204(2):296-302. PubMed ID: 32068488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The diagnostic accuracy of
    Rajwa P; Heidenreich J; Drzezga A; Schmidt M; Shariat SF; Heidenreich A
    Prostate; 2024 Jan; 84(1):74-78. PubMed ID: 37750292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PSMA PET Scan Era: A Changing Paradigm PSMA PET and Lymph Node Dissection for Prostate Cancer Management.
    Haxhimolla J; Kua B; Gilbourd D; Haxhimolla H
    Semin Oncol Nurs; 2020 Aug; 36(4):151044. PubMed ID: 32723519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer.
    van Kalmthout LWM; van Melick HHE; Lavalaye J; Meijer RP; Kooistra A; de Klerk JMH; Braat AJAT; Kaldeway HP; de Bruin PC; de Keizer B; Lam MGEH
    J Urol; 2020 Mar; 203(3):537-545. PubMed ID: 31487220
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Pfister D; Haidl F; Nestler T; Verburg F; Schmidt M; Wittersheim M; Steib F; Heidenreich A
    BJU Int; 2020 Dec; 126(6):679-683. PubMed ID: 32531840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer.
    Kopp D; Kopp J; Bernhardt E; Manka L; Beck A; Gerullis H; Karakiewicz PI; Salomon G; Wiggermann P; Hammerer P; Schiffmann J
    Urol Int; 2022; 106(1):56-62. PubMed ID: 33965965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.
    Maurer T; Gschwend JE; Rauscher I; Souvatzoglou M; Haller B; Weirich G; Wester HJ; Heck M; Kübler H; Beer AJ; Schwaiger M; Eiber M
    J Urol; 2016 May; 195(5):1436-1443. PubMed ID: 26682756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study.
    Gandaglia G; Mazzone E; Stabile A; Pellegrino A; Cucchiara V; Barletta F; Scuderi S; Robesti D; Leni R; Samanes Gajate AM; Picchio M; Gianolli L; Brembilla G; De Cobelli F; van Oosterom MN; van Leeuwen FWB; Montorsi F; Briganti A
    Eur Urol; 2022 Oct; 82(4):411-418. PubMed ID: 35879127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer.
    Yilmaz B; Turkay R; Colakoglu Y; Baytekin HF; Ergul N; Sahin S; Tugcu V; Inci E; Tasci AI; Cermik TF
    Prostate; 2019 Jun; 79(9):1007-1017. PubMed ID: 31012125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accuracy of
    Mandel P; Tilki D; Chun FK; Pristupa E; Graefen M; Klutmann S; Budäus L; Steuber T
    Eur Urol Focus; 2020 Jan; 6(1):71-73. PubMed ID: 30049657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incremental Impact of [
    Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
    Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer.
    Park SY; Zacharias C; Harrison C; Fan RE; Kunder C; Hatami N; Giesel F; Ghanouni P; Daniel B; Loening AM; Sonn GA; Iagaru A
    Radiology; 2018 Aug; 288(2):495-505. PubMed ID: 29786490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective evaluation of the performance of [
    Abufaraj M; Grubmüller B; Zeitlinger M; Kramer G; Seitz C; Haitel A; Baltzer P; Hacker M; Wadsak W; Pfaff S; Wiatr T; Mitterhauser M; Shariat SF; Hartenbach M
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2169-2177. PubMed ID: 31254037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can
    Chen M; Zhuang J; Fu Y; Guo S; Zang S; Ai S; Qiu X; Wang F; Guo H
    J Urol; 2021 Apr; 205(4):1082-1089. PubMed ID: 33207140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, Predictive Factors, and Prediction Nomograms for
    Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
    Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Nandurkar R; van Leeuwen P; Stricker P; Woo H; Kooner R; Yuen C; O'Neill G; Ende D; Cusick T; Ho B; Hickey A; Emmett L
    Br J Radiol; 2019 Mar; 92(1095):20180667. PubMed ID: 30563350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.